BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31801945)

  • 21. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
    Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
    He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
    Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ring finger 220 promotes the stemness and progression of colon cancer cells via Ubiquitin specific peptidase 22-BMI1 axis.
    Yan J; Tan M; Yu L; Jin X; Li Y
    Bioengineered; 2021 Dec; 12(2):12060-12069. PubMed ID: 34753387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
    Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
    Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.
    Yun X; Zhang K; Wang J; Pangeni RP; Yang L; Bonner M; Wu J; Wang J; Nardi IK; Gao M; Raz DJ
    Mol Cancer Res; 2018 Jul; 16(7):1161-1171. PubMed ID: 29720480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair.
    McCann JJ; Vasilevskaya IA; Poudel Neupane N; Shafi AA; McNair C; Dylgjeri E; Mandigo AC; Schiewer MJ; Schrecengost RS; Gallagher P; Stanek TJ; McMahon SB; Berman-Booty LD; Ostrander WF; Knudsen KE
    Cancer Res; 2020 Feb; 80(3):430-443. PubMed ID: 31740444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ubiquitin-Specific Peptidase 22 Contributes to Colorectal Cancer Stemness and Chemoresistance via Wnt/β-Catenin Pathway.
    Jiang S; Song C; Gu X; Wang M; Miao D; Lv J; Liu Y
    Cell Physiol Biochem; 2018; 46(4):1412-1422. PubMed ID: 29689565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells.
    Kim D; Hong A; Park HI; Shin WH; Yoo L; Jeon SJ; Chung KC
    J Cell Physiol; 2017 Dec; 232(12):3664-3676. PubMed ID: 28160502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
    Ahn JY; Lee JS; Min HY; Lee HY
    Oncotarget; 2015 Oct; 6(32):32622-33. PubMed ID: 26416450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
    Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
    Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
    Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
    Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel variant on chromosome 6p21.1 is associated with the risk of developing colorectal cancer: a two-stage case-control study in Han Chinese.
    Xu C; Zhou D; Pan F; Liu Y; Zhang D; Lin A; Miao X; Ni Y; Lv D; Zhang S; Li X; Zhu Y; Lai M
    BMC Cancer; 2016 Oct; 16(1):807. PubMed ID: 27756247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hsp90AB1 Protein is Overexpressed in Non-small Cell Lung Cancer Tissues 
and Associated with Poor Prognosis in Lung Adenocarcinoma Patients].
    Wang M; Feng L; Li P; Han N; Gao Y; Xiao T
    Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):64-9. PubMed ID: 26903158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance.
    Song D; Guo M; Xu S; Song X; Bai B; Li Z; Chen J; An Y; Nie Y; Wu K; Wang S; Zhao Q
    J Exp Clin Cancer Res; 2021 May; 40(1):170. PubMed ID: 33990203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. USP22 Suppresses
    Kosinsky RL; Saul D; Ammer-Herrmenau C; Faubion WA; Neesse A; Johnsen SA
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway.
    Liu YL; Jiang SX; Yang YM; Xu H; Liu JL; Wang XS
    Cell Biochem Biophys; 2012 Jan; 62(1):229-35. PubMed ID: 21928107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.